# KLOW MD — A monograph on the four-peptide KLOW research blend (KPV, GHK-Cu, BPC-157, TB-500)

> Editorial monograph on the four-peptide KLOW research blend. Per-component composition, mechanism summaries, and an explicit accounting of the combination evidence gap.

KLOW is a community designation for a four-peptide research co-formulation: KPV, GHK-Cu, BPC-157, and TB-500. This monograph treats each component on its own terms and is explicit about what the combination evidence does and does not show.

## The short version

KLOW is a co-formulated research vial containing four chemically distinct peptides: KPV, GHK-Cu, BPC-157, and TB-500. The most widely cited composition is 80 mg total — GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, KPV 10 mg — at a 50:10:10:10 mass ratio. None of the four is FDA-approved; the blend as a whole has never been tested in any controlled in-vivo or human study.

Each component has its own separate research record: KPV for reducing gut and cellular inflammation [1][2], GHK-Cu for matrix remodeling and collagen synthesis [7], BPC-157 for tendon and connective-tissue repair [12][13], and TB-500 for cell migration and re-epithelialization via the actin-binding motif of thymosin beta-4 [15][16]. The rationale for combining them is that the four address non-overlapping steps of one repair cascade — but that rationale is mechanistic extrapolation, not combination-study evidence. What the research-use community reports about the blend is on the [effects page](/effects).

## What KLOW is

KLOW is the most-cited community name for a four-peptide research-only co-formulation sold by compounders and research-chemical vendors. The canonical research-vial composition is 80 mg total, divided between GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, and KPV 10 mg [1][7][12]. The four peptides are co-dissolved at fixed mass ratios; they do not form a single chemical complex.

The letters K, L, O, W are a marketing mnemonic and do not correspond to any chemical naming convention. There is no FDA-approved or pharmacopeial KLOW combination product. Component ratios vary across vendors, with a balanced 5 mg : 5 mg : 5 mg : 10 mg variant also reported.

This site is an editorial monograph. It is not a clinic, not a pharmacy, and not a vendor.

## The four components, briefly

KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (residues 11-13). It has been studied as an anti-inflammatory peptide that inhibits NF-κB nuclear translocation, with PepT1-mediated cellular uptake giving it selective accumulation in inflamed gut epithelium and macrophages [1][2][8].

GHK-Cu is a copper-binding tripeptide originally isolated from human plasma in 1973. In cultured human fibroblasts at 1-10 nM, it altered expression of an estimated 4,192 protein-coding genes (about 31.2 percent of the genome) by 50 percent or more, with the strongest signal on extracellular-matrix remodeling, antioxidant defense, and DNA-repair pathways [7].

BPC-157 is a 15-amino-acid synthetic peptide derived from a fragment identified in human gastric juice. In rodent models it has reproducibly improved tendon-to-bone, ligament, muscle-crush, and gastrointestinal-mucosal repair endpoints, with proposed mechanisms involving VEGFR2 phosphorylation and Akt-eNOS activation [12][13][14][20][21].

TB-500 is a synthetic seven-amino-acid acetylated fragment (Ac-LKKTETQ-OH) containing the LKKTET actin-binding motif of native thymosin beta-4 (Tβ4). Nearly all published preclinical data labeled 'thymosin beta-4' uses the full 43-amino-acid protein rather than the seven-amino-acid TB-500 fragment marketed under that name [15][16][17][18].

## The combination evidence

The central honest statement about KLOW is this: no controlled in-vivo study has tested the four-peptide blend against monotherapy of any single component, or against any pairwise or three-peptide subset. Every published synergy claim is a mechanistic extrapolation from the single-agent literature.

The combination rationale, in vendor and preclinical writing, is that the four peptides act on complementary, non-redundant pathways: extracellular-matrix remodeling and gene-expression modulation from GHK-Cu, vascular and connective-tissue support from BPC-157, cytoskeletal remodeling and re-epithelialization from TB-500 (and from native Tβ4 in the underlying literature), and resolution of innate immune inflammation from KPV. That rationale is biologically reasonable. It is not equivalent to evidence that the blend produces additive or synergistic effects in a living animal.

## What this monograph does

The /research page covers each of the four components in turn with the studies the claims rest on. The /dosage page summarizes the doses and routes used in the published preclinical work — strictly as research context, not as a regimen. The /faq page answers the questions readers most commonly bring to the literature on this blend. The /references page lists the underlying papers with DOI and PubMed links.

The goal is a desk-reference register that mirrors a physician's-desk-reference monograph: composition, mechanism, evidence, and regulatory status, presented at the same level of restraint as the literature itself.

---

An independent editorial monograph on the four-peptide KLOW research blend — not a clinic, not a pharmacy, not a vendor.